In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
- Shionogi Licenses Alzheimer’s Disease Treatment to Janssen Pharmaceuticals of US
November 2, 2012
- DSP’s 1st Half Sales Up Mere 0.4 % due to Stagnant Domestic Sales, Profits Show Double-Digit Increase
November 2, 2012
- Takeda’s 1st Half Operating Profits Down 48% due to M&A Costs
November 1, 2012
- FDA Accepts Supplemental NDAs for Latuda for Bipolar Depression: DSP
November 1, 2012
- Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
- EpiPen Marketing Approval Transferred to Pfizer from Mylan
November 1, 2012
- Daiichi Sankyo’s Semiannual Sales Up 6.2% Driven by Ranbaxy
November 1, 2012
- Japanese Pharmaceutical Industry Should Speak More Strongly in Favor of TPP: Paul King
November 1, 2012
- Bayer Announces Positive Results of PIII Trials of Riociguat in Patients with CTEPH, PAH
October 31, 2012
- Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
- All-Case Surveillance Lifted for Humira for Crohn’s Disease: Abbott Japan/Eisai
October 31, 2012
- Asahi Kasei Pharma Launches Global PIII Trial for Recomodulin
October 31, 2012
- Astellas Launches Quadruple Vaccine Quattrovac on October 31
October 31, 2012
- Takeda Files NDA in Japan for Cetilistat for Treatment of Obesity
October 31, 2012
- Mitsubishi Tanabe Reports Growth in 1st-Half Sales with Boost from Remicade, Telavic
October 31, 2012
- Kyowa Hakko Bio to Set Up New Plant in Thailand in Response to Rising Demand for Amino Acids
October 30, 2012
- Equity Participation in ViiV Hoped to Cover Patent Loss of Crestor: Shionogi Pres. Teshirogi
October 30, 2012
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…